GlassScriptPhysician profile
Timothy Queen
NPI 1164422507
$5,291.93
in general payments reported to CMS, 2019-2025
35 companies · $584 in 2025
The $584 reported for 2025 was more than what a typical Otolaryngic Allergy provider received nationally (typical 2025 total: $449).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $910 · 2020: $564 · 2021: $1,351 · 2022: $1,005 · 2023: $353 · 2024: $524 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $1,084.72 | 2019-2025 | |
| Optinose US, INC. | $607.34 | 2019-2025 | |
| Intersect Ent, INC. | $525.94 | 2019-2021 | |
| Kaleo, INC. | $404.32 | 2019-2024 | Auvi-Q |
| Stryker Corporation | $357.21 | 2019-2022 | |
| Glaxosmithkline, LLC. | $218.65 | 2019-2025 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $199.60 | 2021 | |
| Csl Behring | $165.90 | 2019-2022 | |
| Genzyme Corporation | $164.57 | 2019-2022 | |
| Neurent Medical Limited | $162.76 | 2022-2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Abbvie INC. | $157.38 | 2021-2025 | |
| Smith+Nephew, INC. | $121.33 | 2023 | Coblation, Tula |
| Pfizer INC. | $97.69 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $93.26 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $91.46 | 2021-2023 | Dupixent |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $91.02 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $86.95 | 2019-2025 | Tezspire, Airsupra |
| Novartis Pharmaceuticals Corporation | $85.71 | 2019-2022 | |
| Phadia US INC. | $79.04 | 2019-2024 | Immunocap |
| Ars Pharmaceuticals Operations, INC. | $78.49 | 2025 | Neffy |
| Genentech USA, INC. | $77.55 | 2019-2022 | |
| Medtronic, INC. | $52.67 | 2022-2023 | Sinuva |
| Hikma Pharmaceuticals USA | $33.84 | 2022-2023 | Ryaltris |
| Uswm, LLC | $29.00 | 2021 | |
| Watermark Medical, INC. | $28.79 | 2024 | |
| Arbor Pharmaceuticals, INC. | $27.58 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.57 | 2022 | |
| Aimmune Therapeutics, INC. | $23.26 | 2022 | |
| Amgen INC. | $21.43 | 2022 | |
| Inspire Medical Systems, INC. | $20.66 | 2024 | Inspire |
| Lilly USA, LLC | $20.56 | 2025 | Zepbound |
| Becton, Dickinson and Company | $20.36 | 2019 | |
| Acclarent, INC | $16.47 | 2020 | |
| Shire North American Group INC | $10.95 | 2019 | |
| Xoran Technologies LLC | $9.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Queen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.